Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Organogenesis Apligraf

This article was originally published in The Gray Sheet

Executive Summary

Novartis Pharma is set to resume shipments of the bi-layered, living skin substitute under an agreement announced Nov. 20. Novartis suspended its distribution in September after the companies failed to agree on an amended arrangement ("1The Gray Sheet" Sept. 30, 2002, In Brief). Under the new arrangement, the licensing and distribution rights to Apligraf will revert to Organogenesis in June 2003. Subject to approval of a Boston bankruptcy court, the deal is part of a Chapter 11 reorganizing plan filed by Organogenesis in September...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts